Advances in combination therapy for the treatment of estrogen receptor positive breast cancer

IF 8.9 1区化学 Q1 CHEMISTRY, MULTIDISCIPLINARY

Chinese Chemical Letters Pub Date : 2025-06-12 DOI:10.1016/j.cclet.2025.111451

Lijuan Liu , Zhihao Zhao , Feiwan Zou, Wukun Liu, Yunlong Lu

引用次数: 0

Abstract

Breast cancer is a severe problem for women worldwide. Among them, estrogen receptor (ER) positive breast cancer accounted for 70 % of total breast cancer cases, which is the most common subtype. Currently, the main therapy that targeted ER positive breast cancer is endocrine therapy. Herein, we summarized the latest research advances in combination therapies for ER positive breast cancer, focusing on ER as the main therapeutic target. The therapeutic approaches, therapeutic mechanism and resistance will be reviewed and discussed. The combinatorial targets and synergistic effects such as cell cycle-dependent kinase 4/6, phosphatidylinositol-3 kinase, histone deacetylase, bromodomain and extraterminal domain were summarized. In addition, the chemical structures of the inhibitors were also illustrated, along with a brief structure-activity relationship study. Finally, perspective and future directions on breast cancer were proposed and discussed.

Abstract Image

查看原文本刊更多论文

雌激素受体阳性乳腺癌联合治疗的研究进展

乳腺癌是全世界妇女面临的一个严重问题。其中，雌激素受体（ER）阳性乳腺癌占乳腺癌总病例的70% %，是最常见的亚型。目前，针对ER阳性乳腺癌的主要治疗方法是内分泌治疗。在此，我们总结了雌激素受体阳性乳腺癌联合治疗的最新研究进展，重点介绍了雌激素受体作为主要治疗靶点。本文将对其治疗途径、治疗机制和耐药性进行综述和讨论。综述了细胞周期依赖性激酶4/6、磷脂酰肌醇-3激酶、组蛋白去乙酰化酶、溴结构域和外结构域等组合靶点及其协同作用。此外，还说明了抑制剂的化学结构，并进行了简要的构效关系研究。最后，对乳腺癌的研究前景和未来发展方向进行了展望和讨论。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Chinese Chemical Letters 化学-化学综合

CiteScore

14.10

自引率

15.40%

发文量

8969

审稿时长

1.6 months

期刊介绍： Chinese Chemical Letters (CCL) (ISSN 1001-8417) was founded in July 1990. The journal publishes preliminary accounts in the whole field of chemistry, including inorganic chemistry, organic chemistry, analytical chemistry, physical chemistry, polymer chemistry, applied chemistry, etc.Chinese Chemical Letters does not accept articles previously published or scheduled to be published. To verify originality, your article may be checked by the originality detection service CrossCheck.